NCT00002353已完成1 期
A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Immunotherapeutic P3C541b in HIV-1 Seropositive Human Subjects
United Biomedical2 个研究点 分布在 1 个国家开始时间: 2001年8月31日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 试验地点
- 2
研究概览
简要总结
To evaluate an HIV lipopeptide immunotherapeutic, P3C541b, at two dose levels administered subcutaneously in HIV-seropositive patients.
详细描述
Patients are randomized to receive P3C541b or placebo within each of two study groups. Enrollment in the first group will be independent of HLA type, whereas all but two of the patients enrolled in group 2 must have one or more HLA types A33, B8, B27, or Bw62. Treatment in group 2 will not begin until those in group 1 have reached day 14 without serious toxicity.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have:
- •HIV positivity.
- •CD4 count >= 500 cells/mm
- •No evidence of AIDS, persistent diarrhea, fever, oral hairy leukoplakia, herpes varicella-zoster (multidermatomal), oral candidiasis, opportunistic infections, severe cytomegalovirus infection, or disseminated or chronic herpes simplex.
- •Successful establishment of EBV transformed B lymphoblastoid cell line.
- •Most patients in group 2 must possess one or more HLA types A33, B8, B27, or Bw62.
排除标准
- •Co-existing Condition:
- •Patients with the following symptoms or conditions are excluded:
- •Active syphilis.
- •Positive circulating hepatitis B virus antigen.
- •Active clinically significant medical problems.
- •Evidence of psychiatric, medical, or substance abuse problems that would affect ability to participate on study.
- •Occupational or other responsibilities that would prevent completion of study.
- •Concurrent Medication:
- •Other HIV immunotherapeutic.
- •Zidovudine or analog.
- •Investigational therapies for HIV.
- •Patients with the following prior conditions are excluded:
- •History of cancer unless surgically excised with reasonable assurance of cure.
- •History of anaphylaxis or other serious adverse reactions to vaccines.
- •History of serious allergic reaction to any substance that required hospitalization or emergent medical care (e.g., Stevens-Johnson syndrome, bronchospasms, or hypotension).
- •History of autoimmune disease or use of immunosuppressive medications.
- •History of suicide attempts or past psychosis.
- •Prior Medication:
- •Excluded within the past 6 months:
- •HIV immunotherapeutic.
- •Zidovudine or analog.
- •Investigational therapies for HIV. Illicit drug use within past 30 days.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Vaccine Component P3C541b in HIV-1 Seronegative Human SubjectsHIV InfectionsNCT00000845National Institute of Allergy and Infectious Diseases (NIAID)30
已完成
1 期
3BNC117-LS First-in-Human Phase 1 StudyHuman Immunodeficiency VirusNCT03254277Rockefeller University43
已完成
1 期
A Phase I Safety and Immunogenicity Trial of UBI Multivalent HIV-1 Peptide Immunogen in HIV-1 Seronegative Human SubjectsHIV InfectionsNCT00000795National Institute of Allergy and Infectious Diseases (NIAID)28
已完成
1 期
A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected PersonsHIV InfectionsNCT00001060National Institute of Allergy and Infectious Diseases (NIAID)30
已完成
1 期
A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine)HIV InfectionsNCT00000775National Institute of Allergy and Infectious Diseases (NIAID)40